Cargando…

Home Care Program for Managing Oncology Patients during COVID-19 Pandemic. a Tertiary Referral Center Experience

Background COVID-19 pandemic disrupted heath care system all around the world and overwhelmed the capacity of hospital to manage regular patients including cancer patients. We implemented a new program to help managing oncology patients visited our Emergency Rooms (ER) and discharged home. Methods O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gmati, Giamal Edin, Mabsut, Nadine, Matar, Zainab, Alshami, Mona, Shahata, Husam, Alkhesaifi, Areej, Alharbi, Mohamed, Almutairi, Nashmia, Alolayan, Ashwaq, Alzahrani, Mohsen, Algarni, Abdullah, Alhadab, Abdulrahman, Hejazi, Ayman, Alahmari, Bader, Jazieh, Abdul-Rahman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	903.Health Services Research-Malignant Conditions (Myeloid Disease)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330348/ http://dx.doi.org/10.1182/blood-2020-141782

Ejemplares similares

GRUPO ABO E A SUSCETIBILIDADE A INFECÇÃO POR SARS-COV-2: UMA REVISÃO DE LITERATURA
por: Amorim, C.F., et al.
Publicado: (2020)

Platform Incorporating Patient Navigation, Preparative Guidelines, and Hospital at Home May Improve COVID-19 Outcomes for Patients with Myeloid Malignancies
por: Ragon, Brittany Knick, et al.
Publicado: (2021)

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic
por: Jenkins, Kimberly C, et al.
Publicado: (2020)

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program
por: Loke, (Justin) Ching Ting, et al.
Publicado: (2021)

Nursing Management of Frail Patients with Hematologic Malignancies during COVID-19 Pandemia in the Viterbo Domiciliary Care Unit: Data Analysis from March 2020 to March 2021
por: Ciambella, Silvia, et al.
Publicado: (2021)

Acute Leukemia and COVID-19: The Johns Hopkins Experience
por: Miller, Karin Paige, et al.
Publicado: (2021)

Potential Benefits of a 6-Week Exercise and Mindfulness-Based Telehealth Training for HCT Survivors to Meet the Challenges of the COVID-19 Pandemic - a Feasibility Study
por: Ma, David, et al.
Publicado: (2021)

Covid-19 Infection in Hematological Malignancies: Registry Data from India
por: Jain, Arihant, et al.
Publicado: (2021)

Middle East Respiratory Syndrome (MERS) Infection in Hematological and Oncological Patients: A Case Series from a Tertiary Care Center in Saudi Arabia
por: Alaskar, Ahmed, et al.
Publicado: (2019)

1706P Implementing oncology virtual clinics (VC) in response to COVID-19 pandemic: A transformation driven by a crisis
por: Almutairi, N., et al.
Publicado: (2020)

Increased body mass index is a risk factor for acute promyelocytic leukemia
por: Kashanian, Sarah M., et al.
Publicado: (2021)

Models of care for chronic myeloid leukemia patients during the COVID‐19 pandemic in the United Kingdom: Changes in patient attitudes to remote consultations and future implications
por: Duncan, Nicholas, et al.
Publicado: (2021)

DNA methylation analysis improves the prognostication of acute myeloid leukemia
por: Samimi, Hanie, et al.
Publicado: (2021)

Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers
por: Hernlund, Emma, et al.
Publicado: (2021)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect(®) MDS/AML Disease Registry
por: Pollyea, Daniel A., et al.
Publicado: (2020)

The different predictive effects of the intensity and proportion of CD20 expression on the prognosis of B‐lineage acute lymphocyte leukemia
por: Tian, Yun, et al.
Publicado: (2022)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
por: Ishida, Hisashi, et al.
Publicado: (2020)

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies
por: How, Joan, et al.
Publicado: (2022)

Single cell proteogenomic sequencing identifies a relapse‐fated AML subclone carrying FLT3‐ITD with CN‐LOH at chr13q
por: Kim, TaeHyung, et al.
Publicado: (2022)

Predictors of vascular disease in myelodysplastic syndromes
por: Faber, Mark G., et al.
Publicado: (2020)

Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada
por: Cressman, Sonya, et al.
Publicado: (2020)

Fatal renal diseases among patients with hematological malignancies: A population‐based study
por: Li, Sen, et al.
Publicado: (2020)

Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy
por: Galiègue‐Zouitina, Sylvie, et al.
Publicado: (2021)

PD1 expression on bone marrow T‐cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy
por: Bassiouny, Noha, et al.
Publicado: (2020)

Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK
por: Carpenter, Lewis, et al.
Publicado: (2022)

Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy
por: Symeonidou, Vasiliki, et al.
Publicado: (2022)

Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes
por: Rozema, Johanne, et al.
Publicado: (2022)

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)
por: Bossi, Elisa, et al.
Publicado: (2022)

De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China
por: Luo, Jie, et al.
Publicado: (2022)

Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients
por: Wang, Yu‐Hung, et al.
Publicado: (2022)

Molecular characteristics and outcomes in Hispanic and non‐Hispanic patients with acute myeloid leukemia
por: Bradley, Terrence, et al.
Publicado: (2022)

Germline RUNX1 variants in paediatric patients in a French specialised centre
por: Liu, Cécile, et al.
Publicado: (2022)

GSK3 inhibitor enhances gemtuzumab ozogamicin‐induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance
por: Inase, Aki, et al.
Publicado: (2022)

Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2022)

Acute leukemias in pregnant women: Results of a retrospective study at a local tertiary‐care hospital in Japan
por: Kobayashi, Shuhei, et al.
Publicado: (2023)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
por: Ayala, Rosa, et al.
Publicado: (2023)

Prophylaxis with low dose tranexamic acid in acute myeloid leukemia patients undergoing intensive chemotherapy
por: Bønløkke, Søren Thorgaard, et al.
Publicado: (2023)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_53l3v9u1t80v1idpv4cfr0vr7h